返回 Agenda
Session Chair(s)
Alan Shields, PhD
Vice President Patient Centered Outcomes
Adelphi Values, United States
Speaker(s)
Introduction
Alan Shields, PhD
Adelphi Values, United States
Vice President Patient Centered Outcomes
When and Why Should PRO Endpoints be Primary in Oncology Trials?
John H. Powers, MD, FACP
George Washington University School of Medicine, United States
Professor of Clinical Medicine
Evidence Supporting Symptom Burden as a Co-Primary Endpoint Along with Survival
Alicyn Campbell
Genentech, A Member of the Roche Group, United States
Global Head of Patient-Centered Outcomes Research for Oncology Prod. Dev.
An FDA COA Staff Perspective
Ashley F. Slagle, PhD, MS
Aspen Consulting, LLC, United States
Principal, Scientific and Regulatory Consulting
Q&A Panel Discussion
United States